Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Preclinical eye disease biotech sets sights on $17M NYSE IPO

Preclinical eye disease biotech sets sights on $17M NYSE IPO

  • February 18, 2026

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug.

Leave A Comment

Fields (*) Mark are Required